All TIGIT reagents are produced in house and quality controlled, including 3 TIGIT Antibody, 28 TIGIT Gene, 6 TIGIT Lysate, 6 TIGIT Protein, 2 TIGIT qPCR. All TIGIT reagents are ready to use.
Recombinant TIGIT proteins are expressed by HEK293 Cells with fusion tags as C-human IgG1-Fc, C-His.
TIGITantibodies are validated with different applications, which are ELISA, IHC-P.
TIGITcDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each TIGIT of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
Expression host: HEK293 Cells
TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-10 and diminished the production of IL-12p40. In addition, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.